LUNG
Pulmonx Corp (LUNG)
Healthcare • NASDAQ • $1.76-1.40%
- Symbol
- LUNG
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Medical Devices
- Price
- $1.76
- Daily Change
- -1.40%
- Market Cap
- $76.45M
- Trailing P/E
- N/A
- Forward P/E
- -1.89
- 52W High
- $2.89
- 52W Low
- $1.13
- Analyst Target
- $3.40
- Dividend Yield
- 0.00%
- Beta
- 0.34
Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. It offers Zephyr Endobronchial Valve; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also offers LungTraX Platform, a cloud-based quantitative computed tomography analysis service that provides physicians with multiple products, such as LungTraX Connect to improve workup efficiency; LungTraX Detect to enable patient identification; and StratX Lung report that is designed for solution that includes information on emphysema destruction, fissure completeness, and…
Company websiteResearch LUNG on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.